All In Biotech

Drug Trial Radar · NCT06282458

Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt

A Phase 2 Dose-Finding and Proof-of-Concept Study to Evaluate the Effect on Body Composition and Safety of Enobosarm in Patients Treated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Chronic Weight Management

Last checked: Nov 19, 2026Latest source record: Sep 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 168 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

168

Actual

Start

Apr 29, 2024

Primary completion

Apr 11, 2025

Study completion Aug 22, 2025

Sponsor

Lead sponsor
Veru Inc.Industry
Sponsor type
Industry
First posted
Feb 28, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 60 years, up to 100 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective of this study is to assess the effect of enobosarm on total lean mass as measured by DEXA in patients maintained on GLP-1 receptor agonists.

Conditions

  • Muscle Loss
  • Obesity

Interventions

  • EnobosarmDrug

    Enobosarm is an oral, new chemical entity class, SARM, that has demonstrated tissue-selective, dose-dependent improvement in body composition with increases in muscle mass and reduces fat mass, improves insulin resistance, has no masculinizing effects in women, has neutral prostate effects in men, and no increases in hematocrit. Increases in muscle mass have resulted in improvements in muscle strength and physical function.

  • SemaglutideDrug

    Semaglutide for Chronic Weight Management

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The primary endpoint for the study is the percentage change from baseline in total lean body mass at 112 days.Time frame: Day 112

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Pinnacle Trials

    Anniston, Alabama

  • Cullman Clinical Trials

    Cullman, Alabama

  • Artemis Institute for Clinical Research

    San Diego, California

  • Universal Axom Clinical Research

    Doral, Florida

  • Altus Research

    Lake Worth, Florida

  • MARC Research Center

    Louisville, Kentucky

  • Pennington Biomedical

    Baton Rouge, Louisiana

  • DelRicht Research - New Orleans

    New Orleans, Louisiana

  • Centennial Medical Group (CMG)

    Elkridge, Maryland

  • SKY Integrative Medical Center

    Ridgeland, Mississippi

  • Clinvest Headlands LLC

    Springfield, Missouri

  • Palm Research Center

    Las Vegas, Nevada

  • Lillestol Research LLC

    Fargo, North Dakota

  • Clinical Trials of Texas, LLC DBA Flourish Research

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.